20 September 2019

Shareholders’ Rights Directive II: What is new for Luxembourg issuers?

Luxembourg transposed Directive (EU) 2017/828 of 17 May 2017 (“SRD II”) into national law on 1 August 2019, effective 24 August 2019. The key objective of SRD II is the encouragement of effective, sustainable and long-term shareholder engagement in listed companies and to tackle shortcomings of the first shareholders’ rights directive.The new rules impact listed companies, intermediaries, institutional investors, asset managers and proxy advisors. Listed companies face new obligations in relation to shareholder identification, proxy voting, directors’ remuneration and related party transactions.

Please inform yourself in our new GSK Update.

Print


Press contact
Beate Dünschede
+352 271802-29
beate.duenschede@gsk-lux.com

Back

GSK Updates
  • 17.09.2020

    GSK Update: Cross-Border Conversions within the EU are bound for Change: Main Takeaways

    Read more
  • 29.07.2020

    GSK Update: Latest Developments on the Proposed Legalization and Regulation of Cannabis

    Read more
  • 17.07.2020

    GSK Update: New Professional Payment Guarantee

    Read more
Contact person

Dr. Philipp Mössner, LL.M.

Partner

+352 271802-40

philipp.moessner@gsk-lux.com

Anna Lindner

Senior Associate

+352 271802-43

anna.lindner@gsk-lux.com

Chara Papagiannidi, LL.M.

Associate

+352 271802-91

chara.papagiannidi@gsk-lux.com

© GSK Stockmann 2020